NUDT1: A potential independent predictor for the prognosis of patients with oral squamous cell carcinoma. (3rd December 2019)

• Record Type: Journal Article
• Authors: Shen, Yuchen; Zhang, Lei; Piao, Songlin; Li, Lili; Li, Jianhao; Xia, Yanyun; Li, Jichen; Saiyin, Wuliji
• Is Part Of: Journal of oral pathology & medicine. Volume 49:Number 3(2020)
• Page Start: 210
• Page End: 218
• Publication Date: 2019-12-03
• Subjects: NUDT1 -- OSCC -- prognosis; Dentistry -- Periodicals; Teeth -- Diseases -- Periodicals; 617
• DOI: 10.1111/jop.12974
• Languages: English
• ISSNs: 0904-2512

Abstract

Abstract: Objective: The current study was aimed to investigate the association of nudix hydrolase 1 (NUDT1) levels with the prognosis of oral squamous cell carcinoma (OSCC) patients. Material and Methods: Western immunoblotting and qRT‐PCR were used to detect the protein and mRNA levels of NUDT1 in 31 cases of OSCC and normal tissues. The paraffin‐embedded 62 cases of OSCC and 18 normal tissues were collected, and the pathological alterations were assessed by immunohistochemistry. The prognosis of all patients was followed up. Kaplan‐Meier method was used to analyze the survival rate, and Cox regression was used for multivariate analysis. Results: Both the protein and gene levels of NUDT1 were statistically increased ( P = .0007 and P < .0001) in the OSCC tissue and had a significant association with the histopathologic grades of OSCC ( P < .0001 and P = .0223). Immunohistochemistry detection of NUDT1 in 62 human OSCC tissues and 18 normal control tissues showed that NUDT1 expression was significantly increased in OSCC tissue and showed a strong association with histopathologic grades ( P < .0001) and tumor stage ( P = .005). Patients with high NUDT1 expression exhibited poorer overall survival rate (OS) and tumor‐specific survival rate (TSS) than those with low NUDT1 expression ( P < .0001 and P = .0008), and NUDT1 was independent prognostic factors for OS and TSS ( P < .0001 and P < .001). Conclusion: The expression level of NUDT1 might be used to predict the prognosis of OSCC patients.